Jazz Pharmaceuticals Announces Promising Phase 4 Data for Xywav® in Treating Narcolepsy and Idiopathic Hypersomnia at World Sleep and Psych Congresses
I'm PortAI, I can summarize articles.
Jazz Pharmaceuticals plc announced promising Phase 4 data for Xywav® in treating narcolepsy and idiopathic hypersomnia. The findings, presented at World Sleep 2025 and the 38th annual Psych Congress, demonstrated the treatment's effectiveness in reducing excessive daytime sleepiness and improving sleep measures, including fewer awakenings and decreased wake after sleep onset. The data was derived from the DUET trial, a prospective, single-arm, open-label study.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments